Congresos

Neurotoxicology, Degeneration and Protection in Brain Disease States

Mojácar (Almería)

October 15 - 19 1999

The content of this congress, together with other contributions on the topic, are collected in vol. 5 of the series "Strategies for studying brain disorders".

PROGRAMME

S1. NEUROTOXICOLOGICAL CONCOMITANTS OF STRUCTURE AND FUNCTION.

• Tamas Bartfai, Switzerland.
  Cytokines in brain during fever and traumatic brain injury.
• Friedbert Weiss, USA.
  Neurotoxicological consequences of addiction.
• Eduardo Molina-Holgado, Spain.
  Cytokine effects in oligodendrocytes: Implications for the pathogenesis of multiple sclerosis.
• Gaetano Di Chiara, Italy.
  Moving the border between neuroadaptation and neurotoxicity: the case of behavioural sensitization by psychostimulants, dopamine agonists and neuroleptics.
• John Harvey, USA.
  Effects of prenatal exposure to cocaine on the developing brain: anatomical, chemical, physiological and behavioral consecuences.
• Pierre Sokoloff, France.
  A partial dopamine D3 receptor agonist as a new medication for drug addiction.
• Per Eriksson, Sweden.
  Toxicological destruction of cholinergic systems: Implications for psychiatric and neurological conditions.
• Thomas H. Rupniak, UK.
  Oxidative neuropathology and putative chemical entities for Alzheimer's disease.
• João Quevedo, Brazil.
  What may go wrong when memory fails: the main biochemical events underlying memory consolidation and retrieval in rats.
• Eduardo Rodríguez-Farré, Spain.
  Old and new problems in human neurotoxicology.
• Vicente Molina, Spain.
  Neuroimaging studies on degeneration in schizophrenia.
• John W. Olney, USA.
  Neurotoxicological processes in schizophrenia.
• José Borrell, Spain.
  Sensory-motor gating in immune challenged rats: Implications for the etiopathogenesis of schizophrenia.

S2.NEURODEGENERATIVE IMPLICATIONS OF THE DISEASE PROCESSES

• Ryan J. Uitti, USA.
  Neuroprotection conferred by sex in parkinsonism.
• Donald B. Calne, Canada.
  Hereditary versus environmental causes for neurodegeneration.
• Roger L. Albin, USA.
  Huntington disease: A model excitotoxic chronic neurodegeneration.
• Antonio Lobo, Spain.
  Epidemiology of Alzheimer's disease: Implications for Neurodegeneration.
• Isidro Ferrer, Spain.
  Neurotrophin signaling in Alzheimer's disease: Implications in therapeutic strategies.
• Richard Beninger, Canada.
  Cognitive effects of neurotoxic lesions of the nucleus basalis magnocellularis in rats: differential roles for corticopetal versus amygdalopetal projections.
• Bita Moghaddam, USA.
  Metabotropic glutamate receptors and NMDA model of psychosis.
• Jose Mª Delgado, Spain.
  Neuronal adaptability to target removal in motor and premotor systems.
• Michel le Moal, France.
  Perinatal life events: long term consequences.
• Fernando Rodríguez de Fonseca, Spain.
  Role for the endogenous cannabinoid system as a modulator of dopamine transmission in the striatum: Implications for Parkinson's disease and schizophrenia.
• Lewis S. Seiden, USA.
  3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in core body temperature in the rat are affected by small changes in ambient temperature.
• George Ricaurte, USA.
  Amphetamine derivatives and neurodegeneration.
• Barry E. Kosofsky, USA.
  Dose-related alterations in juvenile and adult behavior, neocortical cytoarchitecture and dopaminergic signal transduction following prenatal cocaine exposure in mice.

S3.THE CONCEPT OF NEUROPROTECTION AND ITS REALIZATION

• M.Flint Beal, USA.
  Available and potential neuroprotective agents in free radical onslaught.
• Wojciech Danysz, Germany.
  NMDA receptor antagonists as potential treatment for neurodegenerative dementia. Lesson from Memantine story.
• Khem Jhamandas, Canada.
  Excitotoxicity of quinolinic acid: Modulation by endogenous factors.
• Manuel Vidal-Sanz, Spain.
  Death and neuroprotection of retinal ganglion cells after transient ischemia.
• Chuang C. Chiueh, USA.
  Neuroprotective strategies in Parkinson's disease: Protection against progressive nigral damage induced by free radicals and iron complexes.
• Manfred Gerlach, Germany.
  Protective methods against neurotoxins.
• Trevor Archer, Sweden.
  Restoration and putative protection of MPTP-induced functional deficits.
• Agneta Nordberg, Sweden.
  Neuroprotection in Alzheimer's disease. New strategies for treatment.
• Justo García de Yébenes, Spain.
  Neurotroprophic factors in neurodegenerative disorders.
• Francisco Grandas, Spain.
  The putative neuroprotective role of dopamine agonists in Parkinson's disease.
• Werner J. Schmidt, Germany.
  The neuroprotectant properties of glutamate antagonists and antiglutamatergic drugs.
• Richard M. Kostrzewa, USA.
  Neurotoxicity and neurodegeneration among the shifting sand dunes of protection.